Navigation Links
Medication Adherence - Influenced by Drug or Race?

A recent study at the Ohio State University shows that medication adherence rate in type II diabetes is affected by the race of the patients. Researchers report// that this rate is 12% lower in African Americans in comparison to the whites.

Rajesh Balkrishnan
"That's an unacceptable difference, particularly because African Americans tend to have higher rates of diabetes and disease-related complications," said Rajesh Balkrishnan, a study co-author and the Merrell Dow professor of pharmacy at Ohio State University.

Each of the nearly 2,700 study participants were covered by Medicaid, which provided prescription medication coverage to all enrollees. Still, more than a third of the African Americans and whites in this study failed to take their anti-diabetic medications properly.

"Adherence rates for these types of medications should be better than 90 percent, regardless of who takes them," Balkrishnan said. "Such low rates of adherence may be related to lower socioeconomic status and to lower levels of education.

"Many commercial insurers pay for educators to teach patients the importance of taking their medications as prescribed," he continued. "Medicaid needs to do the same thing. While it invests a lot of money in providing services, it does little to educate its recipients about those services and how to use them. People need to understand the importance of taking their medications."

The results appear in a recent issue of the Journal of the National Medical Association.

The researchers gathered two years' worth of patient information from the North Carolina Medicaid program database. They culled the database for adults with Type 2, or insulin resistant, diabetes, and found 1,527 black and 1,128 white people who fit the criteria.

The information gathered was solely from patients who were taking one of three types medications commonly used to treat diabetes - a thiazolidinedio ne (TZD), a sulfonylurea or metformin.

The researchers determined individual medication adherence rates by calculating how often each person refilled his prescription. They assumed that a prescription filled meant that the previous prescription had been taken.

Many commercial insurers pay for educators to teach patients the importance of taking their medications as prescribed. Medicaid needs to do the same thing. While it invests a lot of money in providing services, it does little to educate its recipients about those services and how to use them.

Based on this calculation alone, the researchers found that the African American diabetic patients in this Medicaid population took their medication as prescribed 54 percent of the time, compared to white diabetic patients who took their medication as prescribed 59 percent of the time.

The researchers also found that, regardless of race, people who took the anti-diabetic drug metformin were 62 percent less likely to take the medication as prescribed.

Other studies have suggested that metformin alone is ineffective at controlling the symptoms of diabetes. Balkrishnan said that most of the patients who took metformin in this study ultimately started to take another anti-diabetic drug, either alone or in combination with metformin.

Balkrishnan conducted the study with Ohio State colleague Rahul Shenolikar, and with researchers from the Wake Forest University School of Medicine and the North Carolina State Center for Health Statistics.

Source: Eurekalert
'"/>




Related medicine news :

1. What happens when Medications go wrong?
2. Medications to Prevent Relapse to Cocaine Use
3. More Elderly Take Inappropriate and Harmful Medications
4. Medications for depression
5. Medications linked to xerostomia and caries
6. Medication recuperates fat distribution in diabetes
7. Pharmacist’s Role in Medication Error
8. The Downside of Asthma Medication
9. Reducing Medication Errors
10. Oral Medication Effective In Combating Eye Infection
11. New Medication May Decrease The Frequency Of Angina Attacks
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/8/2016)... ... December 08, 2016 , ... Mirixa Corporation ... adherence, and other pharmacist-delivered patient care services, has announced the promotions of Karen ... to vice president of sales. , Litsinger joined Mirixa in 2008 after ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... David ... with global law firm Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, ... of the DeviceTalks series, and attorneys from the firm’s global Life Sciences & Medical ...
(Date:12/8/2016)... ... December 08, 2016 , ... Launching ... innovative Unified Instance Manager architecture, meeting the needs of multichannel growth and ... the unattended auto-dialing system without agents, Presence Robodialer, provides greater operational capacity, ...
(Date:12/8/2016)... ... December 08, 2016 , ... STAT courier is pleased to announce that ... for Texas, they are expanding their presence in Dallas. One of the most exciting ... bring new jobs to the Dallas and Forth Worth market. STAT takes pride in ...
(Date:12/8/2016)... ... December 08, 2016 , ... Healthcare is ... Dr. Botelho advocates for the mass media launching of story movements to highlight ... to share their unfortunate experiences; such a movement can generate the network power ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... Dec. 8, 2016 Australia Glaucoma Surgery ... GlobalData,s new report, "Australia Glaucoma Surgery Devices Market ... the Australia Glaucoma Surgery Devices market. The report ... (in units) and average prices (USD) within market ... also provides company shares and distribution shares data ...
(Date:12/8/2016)... KEY FINDINGS The global medical lifting sling ... for growth of the medical lifting sling market are ... high recovery cost of injuries and government initiatives to ... refers to an assistive device that helps caregiver transfer ... the lift and hold the patient. It is important ...
(Date:12/8/2016)... INDIANAPOLIS , Dec. 8, 2016  Eli Lilly ... detailed results of its phase 3 EXPEDITION3 trial at ... (CTAD) meeting. As previously disclosed, solanezumab did not meet ... study of solanezumab initiated in people with mild dementia ... pursue regulatory submissions for solanezumab for the treatment of ...
Breaking Medicine Technology: